Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Cowan

Showing results (261-270 of 269) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 269 results.
Nature Immunology|April 19, 2024
Author Correction: MEF2C regulates NK cell effector functions through control of lipid metabolismJoey H Li, Adalia Zhou, Cassidy D Lee, et al.
Nature Immunology|April 8, 2024
MEF2C regulates NK cell effector functions through control of lipid metabolismJoey H Li, Adalia Zhou, Cassidy D Lee, et al.
Cancer Cell|February 16, 2005
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblEllen Weisberg, Paul W Manley, Werner Breitenstein, et al.
Neuron|September 29, 2017
HDAC5 and Its Target Gene, Npas4, Function in the Nucleus Accumbens to Regulate Cocaine-Conditioned BehaviorsMakoto Taniguchi, Maria B Carreira, Yonatan A Cooper, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 InhibitorAlexei S Karpov, Payman Amiri, Cornelia Bellamacina, et al.
Journal of Medicinal Chemistry|August 24, 2018
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, et al.
Nature|March 23, 2017
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, et al.
Nature Cancer|February 5, 2022
APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasisSonja M Wörmann, Amy Zhang, Fredrik I Thege, et al.
Nature|January 15, 2010
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitorsJianming Zhang, Francisco J Adrián, Wolfgang Jahnke, et al.
Pageof 27

Showing results (261-270 of 269) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 269 results.
Nature Immunology|April 19, 2024
Author Correction: MEF2C regulates NK cell effector functions through control of lipid metabolismJoey H Li, Adalia Zhou, Cassidy D Lee, et al.
Nature Immunology|April 8, 2024
MEF2C regulates NK cell effector functions through control of lipid metabolismJoey H Li, Adalia Zhou, Cassidy D Lee, et al.
Cancer Cell|February 16, 2005
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblEllen Weisberg, Paul W Manley, Werner Breitenstein, et al.
Neuron|September 29, 2017
HDAC5 and Its Target Gene, Npas4, Function in the Nucleus Accumbens to Regulate Cocaine-Conditioned BehaviorsMakoto Taniguchi, Maria B Carreira, Yonatan A Cooper, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 InhibitorAlexei S Karpov, Payman Amiri, Cornelia Bellamacina, et al.
Journal of Medicinal Chemistry|August 24, 2018
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, et al.
Nature|March 23, 2017
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, et al.
Nature Cancer|February 5, 2022
APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasisSonja M Wörmann, Amy Zhang, Fredrik I Thege, et al.
Nature|January 15, 2010
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitorsJianming Zhang, Francisco J Adrián, Wolfgang Jahnke, et al.
Pageof 27